XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific ... ( Oral Presentation Will be Held ...)

HOME >> BIOLOGY >> TECHNOLOGY

XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference

Date:9/6/2007

Oral Presentation Will be Held on September 13, 2007 at the 14th International Symposium on Hepatitis C Virus & Related Viruses to be Held

in Glasgow, Scotland

VALLEY COTTAGE, New York, September 6 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, LSE: XTL, TASE: XTL) announced today that a late breaker abstract, entitled "Potent Small Molecule HCV Inhibitors Affecting NS5A-dependent Functions," was selected for oral presentation at the 14th International Symposium on Hepatitis C Virus & Related Viruses (http://www.hcv2007.com/).

The presentation will take place at 10:30 Greenwich Mean time on Thursday, September 13, 2007, and a press release outlining the data presented will be released by the Company shortly thereafter.

The compounds that will be presented at the conference emerged from the Company's DOS program, aimed at discovering novel hepatitis C inhibitors applying a unique chemistry technology called Diversity Oriented Synthesis. The DOS program was acquired by the Company in late 2005.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: '/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software

Post Your Comments:

(Date:11/6/2009)...v. 6 ,, 3Q09 Corpo...tenza(TM) E.U. Marketing Authorization to Astellas... commercial readiness activities Expanded managem...keting; and Director, Commercial Operations Appoi...Audit Committee chairman , Upcoming 2009 Mi...

(Date:11/6/2009)... 6 Intarcia Therapeutics, Inc. del...ROS® continuous delivery of exenatide) progra...h Annual Diabetes Technology Meeting in San Franci...bin/prnh/20050301/SFTU126LOGO ) ,, Continuous...owers Plasma Glucose, HbA1c and Reduces Weight in ...

(Date:11/5/2009)...v. 5 GenVec, Inc. (Nasda...or the third quarter ended September 30, 2009. Gen... share) for the three months ended September 30, 2...per share) in the comparable quarter of 2008. For ... net loss was $14.1 million ($0.15 per share), com...

(Date:11/5/2009)...Newswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulle...ncer, President and CEO of Imagenetix, will be pre...ICRO Conference on Thursday, December 3rd, at 10:3...About LD MICRO ,, LD MICRO is a by-invitation o...alued companies in the micro-cap space. Since 2002...

Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2 NeurogesX Reports Third Quarter 2009 Results 3 NeurogesX Reports Third Quarter 2009 Results 4 NeurogesX Reports Third Quarter 2009 Results 5 NeurogesX Reports Third Quarter 2009 Results 6 NeurogesX Reports Third Quarter 2009 Results 7 NeurogesX Reports Third Quarter 2009 Results 8 NeurogesX Reports Third Quarter 2009 Results 9 NeurogesX Reports Third Quarter 2009 Results 10 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5 GenVec Reports Third Quarter 2009 Financial Results 2 GenVec Reports Third Quarter 2009 Financial Results 3 GenVec Reports Third Quarter 2009 Financial Results 4 GenVec Reports Third Quarter 2009 Financial Results 5 GenVec Reports Third Quarter 2009 Financial Results 6 Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2

[0] NeurogesX Reports Third Quarter 2009 Results [0] Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting [0] GenVec Reports Third Quarter 2009 Financial Results [0] Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air

... , When: Tuesday, April 22 ... Networking Reception 5:30 p....30 p.m., Where: 610 Hilton Blvd., A...courtaa.com/ann_arbor_city_map_directions.html ), ...ranslation Industry experts ...

...ewswire-FirstCall/ - Victhom Human Bionics,Inc. (V...from the ongoing,human clinical trial of its Close...urostep(TM) for the treatment of patients sufferin...stem lesion. According to the Company, the,initial...eurostep(TM) is,capable of collecting sensory sign...

... 16 /PRNewswire-FirstCall/ - Anavex Life,Sciences ... appointment of,Dr. Dimitri Goundis as Project Dir...res to enter human clinical trials with its lead A...r. Goundis has more than 20 years experience in th...hip positions at Speedel AG (SWX: SPPN),The Medici...

Other Biology Technology:MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting 2 Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system 2 Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 2 Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 3 Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 4

MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system Anavex appoints Dr. Dimitri Goundis to lead Clinical Development

(Date:11/5/2009)...rsity have developed synthetic molecules capable o...HIV-infected cells, as well as to prostate cancer ...urnal of the American Chemical Society , could lea...es. , The molecules called "antibody-recruitin...cruiting molecule targeting prostate cancer" (ARM-...

(Date:11/4/2009)...Long Beach and Riverside are responsible for a sig...a, and the true impact of air pollution and ship e...ated, according to researchers at the University o... appears in an online edition of the American Jou...t of all childhood asthma cases in Long Beach and ...

(Date:11/4/2009)...received more than $10 million in research grants ...stimulus program, bringing thetotal amount of stim...lion. Thirty-three projects achieved stimulus fun...er. , "The university has thoughtfully undertake...rly excellence to federal agency priorities. Thro...

Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2 USC study finds big air pollution impacts on local communities 2 OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2 OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3 Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 1 Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 2 Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 3 Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 4 Cadient Group Brings Home the Gold and Two Bronze Aster Awards 12521 1 Cadient Group Brings Home the Gold and Two Bronze Aster Awards 12521 2 RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 1 RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 2 RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 3 RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 4 RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 5 RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 6

[2] New synthetic molecules trigger immune response to HIV and prostate cancer [0] USC study finds big air pollution impacts on local communities [0] OU achieves $10 million in stimulus grants for 33 projects on the Norman campus

...ts or animals) that we consume on a daily basis ca... as pesticides or antibiotics. A doctoral thesis c... Department of Analytical Chemistry Department of...da (Universidad de Granada) University of Granada...aa and Laura G miz Gracia, proposes new analysis m...

...published in a prestigious American science journa...nd up in fish in as little as three years. Biologi...nada, played a key role in designing and carrying ... mercury emissions from coal-fired power plants an...iately, the amount showing up in fish would begin ...

... cancer tumors from Caucasian and African-American... aggressive in black men. Lead investigator Akhour...d development and research scientist at the Minnea...k mens tumors are more aggressive is based on stud...d only indirect means to measure tumor aggressiven...

Other Biology News:Alternative methods proposed to detect pesticides and antibiotics in water and natural food 2 University of Minnesota study refutes belief that black men have more aggressive prostate cancer 2 University of Minnesota study refutes belief that black men have more aggressive prostate cancer 3

Alternative methods proposed to detect pesticides and antibiotics in water and natural food Groundbreaking Canada-US study proves link between emissions and mercury pollution in fish University of Minnesota study refutes belief that black men have more aggressive prostate cancer

BD BaculoGoldTM Transfection Kit 5 transfections from BD Biosciences Pharmingen

Sf9 Insect Cells from BD Biosciences Pharmingen

UltraClean Plant DNA Isolation Kit from Mo Bio Laboratories, Inc.

Propidium iodide from Research Organics, Inc.

Biology Products:

BD BaculoGoldTM Transfection Kit 5 transfections from BD Biosciences Pharmingen Sf9 Insect Cells from BD Biosciences Pharmingen UltraClean Plant DNA Isolation Kit from Mo Bio Laboratories, Inc.Propidium iodide from Research Organics, Inc.

XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific ...( Oral Presentation Will be Held ...)